The U.S. FDA granted Orphan Drug Designation to ANA-conjugated dactinomycin nanoemulsion for the treatment of Ewing’s sarcoma.  ANA-conjugated dactinomycin nanoemulsion is developed by and in the pipeline of NanoSmart Pharmaceuticals, a biotech company based in Laguna Hills, CA.  It is composed of liposome nano-capsules harboring anti-cancer antibiotics dactinomycin.  The surface of the dactinomycin-containing liposome (nanoemulsion) is coated with NanoSmart’s human-sourced antinuclear antibody (ANA), which is responsible for targeting nanoemulsion to necrosis found in solid tumors thus achieving tumor-specificity for the nanoemulsion.  Ewing’s sarcoma is a rare pediatric cancer of the bone with poor long-term prognosis.  Treatment options include multidrug chemotherapy coupled with surgery and/or radiation.  ANA-conjugated dactinomycin nanoemulsion could potentially achieve anti-tumor specificity while reducing toxicity to patients.